Advanced Accelerator Application SA(ADR) Share Price

Equities

End-of-day quote Nasdaq Other stock markets
-	-

2017	Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	RE
2017	Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	RE

Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	03/11/17	RE
Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	30/10/17	RE
Advanced Accelerator Application : Novartis to buy France's Advanced Accelerator for $3.9 billion	30/10/17	RE

Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications	03/12/18	GL
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer	12/02/18	GL
Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer	01/02/18	GL
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors	26/01/18	GL
Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer	22/01/18	GL

Novartis : Le conseil d'administration d'AAA recommande l'offre de 3,9 mds de dollars de Novartis	06/12/17
Advanced Accelerator Application : Novartis offre 3,9 milliards de dollars pour le français Advanced Accelerator	30/10/17
WDH/Novartis will US-Unternehmen Advanced Accelerator Applications übernehmen	30/10/17
Novartis : compte acquérir Advanced Accelerator Applications pour 3,9 mds de dollars	30/10/17
Novartis : compte acquérir Advanced Accelerator Applications pour 3,9 mds de dollars	30/10/17

Managers	Title	Age	Since
Caio Kugelmas DFI	Director of Finance/CFO	-	-
Sidonie Roswitha Golombowski-Daffner CHM	Chairman	-	30/09/19
Ute Simon CTO	Chief Tech/Sci/R&D Officer	-	31/03/20

Members of the board	Title	Age	Since
Frédéric Collet BRD	Director/Board Member	-	31/12/17
Jessica Toepfer BRD	Director/Board Member	-	31/12/17
Sidonie Roswitha Golombowski-Daffner CHM	Chairman	-	30/09/19

Sector

	1st Jan change	Capi.
MERCK KGAA	+15.82%	79.25B
KYOWA KIRIN CO. LTD.	+14.26%	9.15B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+42.06%	4.46B
SK BIOPHARMACEUTICALS CO., LTD.	-14.54%	4.9B
YUHAN CORPORATION	+9.01%	4.09B
INDIVIOR PLC	+21.27%	2.49B
BETTA PHARMACEUTICALS CO., LTD.	-27.22%	2.17B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+15.83%	2.1B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-39.50%	1.89B